{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:39:57Z","timestamp":1791430797196,"version":"4.3.3"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.eururo.2017.03.010","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T21:16:32Z","timestamp":1490908592000},"page":"354-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":210,"title":["Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset"],"prefix":"10.1016","volume":"72","author":[{"given":"Woonyoung","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Aine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco X.","family":"Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Kiltie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Milsom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2017.03.010_bib0440","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2017.03.010_bib0445","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccr.2004.08.002","article-title":"Focus on bladder cancer","volume":"6","author":"Dinney","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2017.03.010_bib0450","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.03.010_bib0455","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1126\/science.286.5439.531","article-title":"Molecular classification of cancer: class discovery and class prediction by gene expression monitoring","volume":"286","author":"Golub","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.eururo.2017.03.010_bib0460","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2017.03.010_bib0465","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2017.03.010_bib0470","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2017.03.010_bib0490","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr2635","article-title":"Phenotypic and molecular characterization of the Claudin-low intrinsic subtype of breast cancer","volume":"12","author":"Prat","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0495","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0500","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.03.010_bib0485","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrclinonc.2011.178","article-title":"Practical implications of gene-expression-based assays for breast oncologists","volume":"9","author":"Prat","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0505","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","article-title":"Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer","volume":"366","author":"von Minckwitz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.03.010_bib0510","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1535-6108(04)00112-6","article-title":"Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression","volume":"5","author":"Chung","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2017.03.010_bib0515","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1073\/pnas.0402870102","article-title":"Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme","volume":"102","author":"Liang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2017.03.010_bib0520","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2017.03.010_bib0525","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.cell.2014.06.049","article-title":"Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin","volume":"158","author":"Hoadley","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2017.03.010_bib0540","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2017.03.010_bib0545","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1158\/1078-0432.CCR-14-1215","article-title":"Invasive bladder cancer: genomic insights and therapeutic promise","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0550","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2017.03.010_bib0555","first-page":"401","article-title":"Histogenesis of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats","volume":"60","author":"Ito","year":"1969","journal-title":"Gan"},{"key":"10.1016\/j.eururo.2017.03.010_bib0560","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2017.03.010_bib0565","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2017.03.010_bib0570","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ng.3557","article-title":"Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors","volume":"48","author":"Kim","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2017.03.010_bib0575","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","article-title":"APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity","volume":"5","author":"Swanton","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2017.03.010_bib0580","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.celrep.2014.04.038","article-title":"Mutational context and diverse clonal development in early and late bladder cancer","volume":"7","author":"Nordentoft","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.eururo.2017.03.010_bib0585","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1126\/science.1253462","article-title":"Spatial and temporal diversity in genomic instability processes defines lung cancer evolution","volume":"346","author":"de Bruin","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.eururo.2017.03.010_bib0590","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/ng.907","article-title":"Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder","volume":"43","author":"Gui","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2017.03.010_bib0595","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1158\/0008-5472.CAN-09-4213","article-title":"Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome","volume":"70","author":"Lindgren","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0600","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1126\/science.2024123","article-title":"Identification of p53 gene mutations in bladder cancers and urine samples","volume":"252","author":"Sidransky","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.eururo.2017.03.010_bib0605","first-page":"784","article-title":"Two molecular pathways to transitional cell carcinoma of the bladder","volume":"54","author":"Spruck","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0610","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1158\/1078-0432.CCR-06-0206","article-title":"The p53 pathway and outcome among patients with T1G3 bladder tumors","volume":"12","author":"Lopez-Knowles","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0615","doi-asserted-by":"crossref","first-page":"e67222","DOI":"10.1371\/journal.pone.0067222","article-title":"Detailed analysis of focal chromosome arm 1q and 6p amplifications in urothelial carcinoma reveals complex genomic events on 1q, and SOX4 as a possible auxiliary target on 6p","volume":"8","author":"Eriksson","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2017.03.010_bib0620","first-page":"1131","article-title":"c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization","volume":"146","author":"Sauter","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0625","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/ng.2799","article-title":"Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy","volume":"45","author":"Balbas-Martinez","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2017.03.010_bib0630","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2017.03.010_bib0635","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0640","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/ng.2798","article-title":"Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation","volume":"45","author":"Guo","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2017.03.010_bib0645","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nrurol.2013.253","article-title":"Bladder cancer: STAG2 in the spotlight\u2014have genomic studies identified a plausible biomarker?","volume":"10","author":"Razzak","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0650","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/ng.2800","article-title":"Frequent truncating mutations of STAG2 in bladder cancer","volume":"45","author":"Solomon","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2017.03.010_bib0655","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/hmg\/ddt589","article-title":"Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes","volume":"23","author":"Taylor","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.eururo.2017.03.010_bib0660","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","article-title":"Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome","volume":"65","author":"Allory","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0665","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1126\/science.1260200","article-title":"Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer","volume":"347","author":"Borah","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.eururo.2017.03.010_bib0670","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.eururo.2017.03.010_bib0675","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.eururo.2013.08.057","article-title":"Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine","volume":"65","author":"Hurst","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0680","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine","volume":"73","author":"Kinde","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0685","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1158\/1078-0432.CCR-14-0330","article-title":"Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer","volume":"20","author":"Nickerson","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0690","doi-asserted-by":"crossref","first-page":"17426","DOI":"10.1073\/pnas.1310522110","article-title":"TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism","volume":"110","author":"Rachakonda","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2017.03.010_bib0695","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2017.03.010_bib0700","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/12615","article-title":"Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas","volume":"23","author":"Cappellen","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2017.03.010_bib0705","first-page":"1265","article-title":"The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate","volume":"61","author":"van Rhijn","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0710","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.bjc.6606016","article-title":"Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo","volume":"104","author":"Lamont","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2017.03.010_bib0715","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1038\/onc.2009.280","article-title":"Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner","volume":"28","author":"di Martino","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.eururo.2017.03.010_bib0720","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/hmg\/dds486","article-title":"Oncogenic FGFR3 gene fusions in bladder cancer","volume":"22","author":"Williams","year":"2013","journal-title":"Hum Mol Gen"},{"key":"10.1016\/j.eururo.2017.03.010_bib0725","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3678","article-title":"A new tumor suppressor role for the Notch pathway in bladder cancer","volume":"20","author":"Rampias","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2017.03.010_bib0730","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1172\/JCI78185","article-title":"NOTCH pathway inactivation promotes bladder cancer progression","volume":"125","author":"Maraver","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2017.03.010_bib0735","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/ncb2956","article-title":"Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma","volume":"16","author":"Shin","year":"2014","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0740","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ccell.2014.09.001","article-title":"Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors","volume":"26","author":"Shin","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2017.03.010_bib0745","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ng1061","article-title":"Identifying distinct classes of bladder carcinoma using microarrays","volume":"33","author":"Dyrskjot","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2017.03.010_bib0750","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1158\/1078-0432.CCR-04-2409","article-title":"Bladder cancer outcome and subtype classification by gene expression","volume":"11","author":"Blaveri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0755","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2005.03.2375","article-title":"Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays","volume":"24","author":"Sanchez-Carbayo","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0760","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/0008-5472.CAN-03-3620","article-title":"Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification","volume":"64","author":"Dyrskjot","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0765","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1158\/1078-0432.CCR-04-2095","article-title":"A molecular signature in superficial bladder carcinoma predicts clinical outcome","volume":"11","author":"Dyrskjot","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0770","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1158\/1078-0432.CCR-06-2940","article-title":"Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study","volume":"13","author":"Dyrskjot","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0775","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.eururo.2015.02.021","article-title":"A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma","volume":"68","author":"Patschan","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0780","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0785","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","article-title":"Toward a molecular pathologic classification of urothelial carcinoma","volume":"183","author":"Sjodahl","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0790","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2017.03.010_bib0795","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2017.03.010_bib0800","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.1038\/srep10957","article-title":"Biological determinants of bladder cancer gene expression subtypes","volume":"5","author":"Aine","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2017.03.010_bib0805","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrurol.2014.129","article-title":"Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer","volume":"11","author":"Choi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0810","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.eururo.2014.05.006","article-title":"New insights into subtypes of invasive bladder cancer: considerations of the clinician","volume":"66","author":"McConkey","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0815","doi-asserted-by":"crossref","first-page":"244ra91","DOI":"10.1126\/scitranslmed.3008970","article-title":"EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype","volume":"6","author":"Rebouissou","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2017.03.010_bib0820","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0825","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.hoc.2014.11.003","article-title":"Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer","volume":"29","author":"McConkey","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.eururo.2017.03.010_bib0830","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.03.010_bib0835","doi-asserted-by":"crossref","first-page":"e85902","DOI":"10.1172\/jci.insight.85902","article-title":"Claudin-low bladder tumors are immune infiltrated and actively immune suppressed","volume":"1","author":"Kardos","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.eururo.2017.03.010_bib0840","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1158\/1078-0432.CCR-15-0876","article-title":"A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition","volume":"22","author":"Mak","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.03.010_bib0845","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/BLC-150037","article-title":"Bladder cancer molecular taxonomy: summary from a consensus meeting","volume":"2","author":"Lerner","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2017.03.010_bib0530","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/2159-8290.CD-12-0462","article-title":"The genomic landscape of breast cancer as a therapeutic roadmap","volume":"3","author":"Ellis","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2017.03.010_bib0850","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2017.03.010_bib0855","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ydbio.2013.12.028","article-title":"Identification of ELF3 as an early transcriptional regulator of human urothelium","volume":"386","author":"Bock","year":"2014","journal-title":"Dev Biol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0860","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1242\/jcs.01042","article-title":"Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme","volume":"117","author":"Varley","year":"2004","journal-title":"J Cell Sci"},{"key":"10.1016\/j.eururo.2017.03.010_bib0865","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","article-title":"ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy","volume":"69","author":"Groenendijk","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.03.010_bib0870","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/ncb3038","article-title":"Bladder cancers arise from distinct urothelial sub-populations","volume":"16","author":"Van Batavia","year":"2014","journal-title":"Nat Cell Biol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817301756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817301756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T23:55:10Z","timestamp":1535932510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283817301756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0302283817301756"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2017.03.010","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2017.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}